/PODD
Insulet Corporation
PODD • NASDAQPODD • NASDAQ • Healthcare
$219.84-6.88%-16.23
$219.84-6.88%(-16.23)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
100Bullish
Risk
63Low Risk
Momentum
5Negative
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
71.6%▲1.8pp
Revenue after COGS
Operating
17.5%▲2.6pp
After operating expenses
Net
9.1%▼11.1pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
80.9
Price vs earnings
EV/EBITDA
34.6
Enterprise value
FCF Yield
1.9%
Cash generation
Earnings Yield
1.2%
Inverse of P/E
Capital Efficiency
13
GoAI Quality ScoreFair
ROEReturn on Equity
16.3%Strong
ROAReturn on Assets
7.7%Strong
ROICReturn on Invested Capital
13.6%Strong
Financial Health
Current RatioHealthy
2.78
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
0.57x
Debt repayment capacity (<3x)
Income QualityStrong
2.30
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.70B | $1.31B | $1.10B |
| Gross Profit | $1.94B | $1.45B | $1.16B | $805.60M | $752.10M |
| Gross Margin | 71.6% | 69.8% | 68.3% | 61.7% | 68.4% |
| Operating Income | $473.80M | $308.90M | $220.00M | $37.60M | $126.00M |
| Net Income | $247.10M | $418.30M | $206.30M | $4.60M | $16.80M |
| Net Margin | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% |
| EPS | $3.51 | $5.97 | $2.96 | $0.07 | $0.25 |
Average Price Target
$357.25▲ 62.5% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Insulet Corporation, the average price target is $357.25, with a high forecast of $435.00 and a low forecast of $286.00. The average price target represents a 62.5% increase from the current price of $219.84.
Highest
$435.00
Average
$357.25
Lowest
$286.00
Rating Distribution
Strong Buy
0
0%
Buy
36
73%
Hold
10
20%
Sell
3
6%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Citigroup● Maintain
Buy
2026-03-11Citigroup● Maintain
Buy
2026-02-19Truist Securities● Maintain
Buy
2026-02-19Bernstein● Maintain
Outperform
2026-02-19JP Morgan● Maintain
Overweight
2026-02-19Goldman Sachs● Maintain
Buy
2026-02-19Leerink Partners● Maintain
Outperform
2026-02-19Oppenheimer● Maintain
Outperform
2026-02-19Canaccord Genuity● Maintain
Buy
2026-02-19Evercore ISI Group● Maintain
Outperform
2026-02-19Earnings History & Surprises
BEAT RATE
83%
Last 18 quarters
AVG SURPRISE
+45.8%
EPS vs Estimate
BEATS / MISSES
15/3
Last 18 quarters
LATEST EPS
$1.55
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+4.7%
$1.55 vs $1.48
Q4 '25
+8.8%
$1.24 vs $1.14
Q3 '25
+27.2%
$1.17 vs $0.92
Q2 '25
+29.1%
$1.02 vs $0.79
Q1 '25
+15.0%
$1.15 vs $1.00
Q4 '24
+18.4%
$0.90 vs $0.76
Q3 '24
-2.5%
$0.55 vs $0.56
Q2 '24
+87.2%
$0.73 vs $0.39
Q1 '24
+112.1%
$1.40 vs $0.66
Q4 '23
+77.5%
$0.71 vs $0.40
Q3 '23
+46.2%
$0.38 vs $0.26
Q2 '23
+155.6%
$0.23 vs $0.09
No investor questions available.
Latest News
No news available